Brachytherapy · 2025
Assessment of brachytherapy-induced prostate edema on postimplant dosimetric analysis in patients treated with magnetic resonance imaging-assisted radiosurgery (MARS).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marqueen Kathryn E, Corrigan Kelsey L, Prajapati Surendra, Kudchadker Rajat J, Manzar Gohar, Cha Elaine, Mok Henry, Tang Chad, Hassanzadeh Comron, Mohamad Osama, Frank Steven J
Аннотация
PURPOSE: Brachytherapy-induced prostate edema (PE) can result in altered target dose coverage in prostate cancer patients treated with low-dose-rate (LDR) brachytherapy. While visualization of PE on CT is limited, PE is evident on magnetic resonance imaging (MRI) day 0 (D0) postimplant assessment, a critical step in the MRI-assisted radiosurgery (MARS) framework that improves LDR brachytherapy quality assurance. This study investigated PE in patients treated with MARS to analyze the effect on postimplant dosimetry and further optimize the treatment-planning process.
MATERIALS AND METHODS: We identified 317 patients with low-risk to intermediate-risk prostate cancer treated with cesium-131, iodine-125, or palladium-103 MARS definitive monotherapy from 2016 to 2021. Postimplant dosimetry was performed using MRI on D0. Simple linear regression with Pearson correlation analysis and ordinary ANOVA were used for analysis.
RESULTS: The median D0 prostate volume was 29% higher (IQR, 16%-42%) compared with preimplant measurement, with no significant differences in PE magnitude by isotope (p = 0.33) or number of needles implanted (p = 0.70). PE magnitude decreased with increasing preplan prostate size (p < 0.001). Greater PE was associated with decreased D0 prostate V100 (p < 0.001), V150 (p < 0.001), and D90 (p < 0.001), but was not associated with V200 (p = 0.06), and >98% implants achieved D90/prescription dose >90%. Greater PE was associated with decreased rectum V100 (p = 0.02).
CONCLUSIONS: MRI on D0 confirmed PE after LDR brachytherapy. PE was not significantly different between isotopes, supporting the use of the same preplan target-volume margins among isotopes. Greater PE was associated with decreased prostate V100, V150, and D90, without significant impact on overall implant quality.
MATERIALS AND METHODS: We identified 317 patients with low-risk to intermediate-risk prostate cancer treated with cesium-131, iodine-125, or palladium-103 MARS definitive monotherapy from 2016 to 2021. Postimplant dosimetry was performed using MRI on D0. Simple linear regression with Pearson correlation analysis and ordinary ANOVA were used for analysis.
RESULTS: The median D0 prostate volume was 29% higher (IQR, 16%-42%) compared with preimplant measurement, with no significant differences in PE magnitude by isotope (p = 0.33) or number of needles implanted (p = 0.70). PE magnitude decreased with increasing preplan prostate size (p < 0.001). Greater PE was associated with decreased D0 prostate V100 (p < 0.001), V150 (p < 0.001), and D90 (p < 0.001), but was not associated with V200 (p = 0.06), and >98% implants achieved D90/prescription dose >90%. Greater PE was associated with decreased rectum V100 (p = 0.02).
CONCLUSIONS: MRI on D0 confirmed PE after LDR brachytherapy. PE was not significantly different between isotopes, supporting the use of the same preplan target-volume margins among isotopes. Greater PE was associated with decreased prostate V100, V150, and D90, without significant impact on overall implant quality.